Literature DB >> 16327496

In vitro osteogenic differentiation and in vivo bone-forming capacity of human isogenic jaw periosteal cells and bone marrow stromal cells.

Claude Jaquiéry1, Stefan Schaeren, Jian Farhadi, Pierre Mainil-Varlet, Christoph Kunz, Hans-Florian Zeilhofer, Michael Heberer, Ivan Martin.   

Abstract

OBJECTIVE: To compare the in vitro osteogenic differentiation and in vivo ectopic bone forming capacity of human bone marrow stromal cells (BMSCs) and jaw periosteal cells (JPCs), and to identify molecular predictors of their osteogenic capacity. SUMMARY BACKGROUND DATA: JPC could be an appealing alternative to BMSC for the engineering of cell-based osteoinductive grafts because of the relatively easy access to tissue with minimal morbidity. However, the extent of osteogenic capacity of JPC has not yet been established or compared with that of BMSC.
METHODS: BMSCs and JPCs from the same donors (N = 9), expanded for 2 passages, were cultured for 3 weeks in osteogenic medium either in monolayers (Model I) or within 3-dimensional porous ceramic scaffolds, following embedding in fibrin gel (Model II). Cell-fibrin-ceramic constructs were also implanted ectopically in nude mice for 8 weeks (Model III). Cell differentiation in vitro was assessed biochemically and by real-time RT-PCR. Bone formation in vivo was quantified by computerized histomorphometry.
RESULTS: JPCs had lower alkaline phosphatase activity, deposited smaller amounts of calcium (Model I), and expressed lower mRNA levels of bone sialoprotein, osteopontin, and osterix (Models I and II) than BMSCs. JPCs produced ectopic bone tissue at lower frequency and amounts (Model III) than BMSCs. Bone sialoprotein, osteopontin, and osterix mRNA levels by BMSCs or JPCs in Model II were markedly higher than in Model I and significantly more expressed by cells that generated bone tissue in Model III.
CONCLUSIONS: Our data indicate that JPCs, although displaying features of osteogenic cells, would not be as reliable as BMSCs for cell-based bone tissue engineering, and suggest that expression of osteoblast-related markers in vitro could be used to predict whether cells would be osteoinductive in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16327496      PMCID: PMC1409890          DOI: 10.1097/01.sla.0000189572.02554.2c

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  36 in total

1.  Repair of large bone defects with the use of autologous bone marrow stromal cells.

Authors:  R Quarto; M Mastrogiacomo; R Cancedda; S M Kutepov; V Mukhachev; A Lavroukov; E Kon; M Marcacci
Journal:  N Engl J Med       Date:  2001-02-01       Impact factor: 91.245

2.  Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: Implications for their use in cell therapy.

Authors:  A Banfi; A Muraglia; B Dozin; M Mastrogiacomo; R Cancedda; R Quarto
Journal:  Exp Hematol       Date:  2000-06       Impact factor: 3.084

3.  Three-dimensional cellular development is essential for ex vivo formation of human bone.

Authors:  S Kale; S Biermann; C Edwards; C Tarnowski; M Morris; M W Long
Journal:  Nat Biotechnol       Date:  2000-09       Impact factor: 54.908

4.  Donor variation in the growth properties and osteogenic potential of human marrow stromal cells.

Authors:  D G Phinney; G Kopen; W Righter; S Webster; N Tremain; D J Prockop
Journal:  J Cell Biochem       Date:  1999-12-01       Impact factor: 4.429

5.  The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation.

Authors:  Kazuhisa Nakashima; Xin Zhou; Gary Kunkel; Zhaoping Zhang; Jian Min Deng; Richard R Behringer; Benoit de Crombrugghe
Journal:  Cell       Date:  2002-01-11       Impact factor: 41.582

6.  In vitro-cultivation of human periosteum derived cells in bioresorbable polymer-TCP-composites.

Authors:  Ulrike Arnold; Klaus Lindenhayn; Carsten Perka
Journal:  Biomaterials       Date:  2002-06       Impact factor: 12.479

7.  Real-time quantitative RT-PCR analysis of human bone marrow stromal cells during osteogenic differentiation in vitro.

Authors:  Oliver Frank; Manuel Heim; Marcel Jakob; Andrea Barbero; Dirk Schäfer; Igor Bendik; Walter Dick; Michael Heberer; Ivan Martin
Journal:  J Cell Biochem       Date:  2002       Impact factor: 4.429

8.  Bone tissue-engineered implants using human bone marrow stromal cells: effect of culture conditions and donor age.

Authors:  S C Mendes; J M Tibbe; M Veenhof; K Bakker; S Both; P P Platenburg; F C Oner; J D de Bruijn; C A van Blitterswijk
Journal:  Tissue Eng       Date:  2002-12

Review 9.  Marrow stromal stem cells.

Authors:  P Bianco; P Gehron Robey
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

10.  Skeletal malformations caused by overexpression of Cbfa1 or its dominant negative form in chondrocytes.

Authors:  C Ueta; M Iwamoto; N Kanatani; C Yoshida; Y Liu; M Enomoto-Iwamoto; T Ohmori; H Enomoto; K Nakata; K Takada; K Kurisu; T Komori
Journal:  J Cell Biol       Date:  2001-04-02       Impact factor: 10.539

View more
  16 in total

1.  A study of enamel matrix proteins on differentiation of porcine bone marrow stromal cells into cementoblasts.

Authors:  A M Song; R Shu; Y F Xie; Z C Song; H Y Li; X F Liu; X L Zhang
Journal:  Cell Prolif       Date:  2007-06       Impact factor: 6.831

2.  Analysis of OPLA scaffolds for bone engineering constructs using human jaw periosteal cells.

Authors:  Dorothea Alexander; Jürgen Hoffmann; Adelheid Munz; Björn Friedrich; Jürgen Geis-Gerstorfer; Siegmar Reinert
Journal:  J Mater Sci Mater Med       Date:  2007-12-25       Impact factor: 3.896

Review 3.  Concise review: the periosteum: tapping into a reservoir of clinically useful progenitor cells.

Authors:  Hana Chang; Melissa L Knothe Tate
Journal:  Stem Cells Transl Med       Date:  2012-05-30       Impact factor: 6.940

4.  In vivo formation of bone and haematopoietic territories by transplanted human bone marrow stromal cells generated in medium with and without osteogenic supplements.

Authors:  Sergei A Kuznetsov; Mahesh H Mankani; Pamela Gehron Robey
Journal:  J Tissue Eng Regen Med       Date:  2011-11-03       Impact factor: 3.963

5.  Methylation of the promoter A of estrogen receptor alpha gene in hBMSC and osteoblasts and its correlation with homocysteine.

Authors:  Haihong Lv; Xiaolan Ma; Tuanjie Che; Yirong Chen
Journal:  Mol Cell Biochem       Date:  2011-04-27       Impact factor: 3.396

6.  Discovery of surface biomarkers for cell mechanophenotype via an intracellular protein-based enrichment strategy.

Authors:  Megan E Dempsey; Graylen R Chickering; Rafael D González-Cruz; Vera C Fonseca; Eric M Darling
Journal:  Cell Mol Life Sci       Date:  2022-05-27       Impact factor: 9.207

Review 7.  Bone tissue engineering with human stem cells.

Authors:  Darja Marolt; Miomir Knezevic; Gordana Vunjak Novakovic
Journal:  Stem Cell Res Ther       Date:  2010-05-04       Impact factor: 6.832

8.  Primary human alveolar bone cells isolated from tissue samples acquired at periodontal surgeries exhibit sustained proliferation and retain osteogenic phenotype during in vitro expansion.

Authors:  Darja Marolt; Matjaz Rode; Nevenka Kregar-Velikonja; Matjaz Jeras; Miomir Knezevic
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

9.  In vivo ectopic implantation model to assess human mesenchymal progenitor cell potential.

Authors:  Ander Abarrategi; Raquel Perez-Tavarez; Miguel Angel Rodriguez-Milla; Isabel Cubillo; Francisca Mulero; Arantzazu Alfranca; Jose Luis Lopez-Lacomba; Javier García-Castro
Journal:  Stem Cell Rev Rep       Date:  2013-12       Impact factor: 5.739

10.  Scaffold-Free Fabrication of Osteoinductive Cellular Constructs Using Mouse Gingiva-Derived Induced Pluripotent Stem Cells.

Authors:  Hiroko Okawa; Hiroki Kayashima; Jun-Ichi Sasaki; Jiro Miura; Yuya Kamano; Yukihiro Kosaka; Satoshi Imazato; Hirofumi Yatani; Takuya Matsumoto; Hiroshi Egusa
Journal:  Stem Cells Int       Date:  2016-03-27       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.